Uniunea Europeană - română - EMA (European Medicines Agency)

zoetis belgium sa - synthetic peptide analogue of gnrf conjugated to diptheria toxoid - imunologii pentru suidae - male pigs (from 8 weeks of age); female pigs (from 14 weeks of age) - male pigs:induction of antibodies against gnrf to produce a temporary immunological suppression of testicular function. for use as an alternative to physical castration for the reduction of boar taint caused by the key boar taint compound androstenone, in entire male pigs following the onset of puberty. un alt factor care contribuie la mâncarea de mistreți, skatole, poate fi de asemenea redus ca efect indirect. comportamentele agresive și sexuale (de montare) sunt de asemenea reduse. female pigs:induction of antibodies against gnrf to produce a temporary immunological suppression of ovarian function (suppression of oestrus) in order to reduce the incidence of unwanted pregnancies in gilts intended for slaughter, and to reduce the associated sexual behaviour (standing oestrus).

Uniunea Europeană - română - EMA (European Medicines Agency)

eli lilly nederland b.v. - baricitinib - artrita, reumatoida - imunosupresoare - rheumatoid arthritisbaricitinib is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (dmards). olumiant poate fi utilizat ca monoterapie sau în asociere cu metotrexat. atopic dermatitisolumiant is indicated for the treatment of moderate to severe atopic dermatitis in adult and paediatric patients 2 years of age and older who are candidates for systemic therapy. alopecia areatabaricitinib is indicated for the treatment of severe alopecia areata in adult patients (see section 5. juvenile idiopathic arthritisbaricitinib is indicated for the treatment of active juvenile idiopathic arthritis in patients 2 years of age and older who have had an inadequate response or intolerance to one or more prior conventional synthetic or biologic dmards:- polyarticular juvenile idiopathic arthritis (polyarticular rheumatoid factor positive [rf+] or negative [rf-], extended oligoarticular),- enthesitis related arthritis, and- juvenile psoriatic arthritis. baricitinib may be used as monotherapy or in combination with methotrexate.

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

sintetica gmbh - germania - phenylephrinum - sol inj./perf. - 0,1mg/ml - stimulante cardiace excl. glicozizi cardiotonici med.adrenergice si dopaminergice

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

sintetica gmbh - germania - phenylephrinum - sol. inj. - 10 mg/ml - stimulante cardiace excl. glicozizi cardiotonici med.adrenergice si dopaminergice

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

sintetica gmbh - germania - droperidolum - sol inj. - 0,5mg/ml - antipsihotice derivati de butirofenona

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

sintetica gmbh - germania - baclofenum - sol inj. - 0,05mg/ml - miorelaxante centrale alte miorelaxante cu actiune centrala

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

sintetica gmbh - germania - baclofenum - sol inj. - 0,5mg/ml - miorelaxante centrale alte miorelaxante cu actiune centrala

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

sintetica gmbh - germania - baclofenum - sol inj. - 2mg/ml - miorelaxante centrale alte miorelaxante cu actiune centrala

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

sirton pharmaceuticals spa - italia - prilocainum - sol. inj. - 20mg/ml - anestezice locale amide

Uniunea Europeană - română - EMA (European Medicines Agency)

amryt pharmaceuticals dac - octreotide acetate - acromegalie - hormoni hipofizari și hipotalamici și analogi - mycapssa is indicated for maintenance treatment in adult patients with acromegaly who have responded to and tolerated treatment with somatostatin analogues.